Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Therapy for Acquired Immunodeficiency Syndrome: Implantation of Cultured Thymic Fragments

Therapy for Acquired Immunodeficiency Syndrome: Implantation of Cultured Thymic Fragments Abstract The most serious consequence of infection with the human T-cell leukemia-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) is the severely altered immune state underlying the opportunistic diseases that define the acquired immunodeficiency syndrome (AIDS). Control of the spread of HTLV-III/LAV infection in the absence of a vaccine is dependent on risk reduction among homosexual/bisexual males, users of illicit intravenous drugs, and heterosexual sexual partners of these high-risk individuals. Exclusion from the blood supply of potentially infected blood and blood products with screening for antibody to HTLV-III/LAV should prevent approximately 2% of AIDS cases. Therapy of infected individuals with and without AIDS remains an elusive goal but will probably require effective antiviral therapy and immunomodulation. The rationale underlying the attempts to enhance the immune status of these patients is the observation that the defect associated with HTLV-III/LAV infection is due to depletion of T-helper (T4 + ) References 1. Fauci AS, Masur H, Gehman EP, et al: The acquired immunodeficiency syndrome: An update. Ann Intern Med 1985;102: 800-813.Crossref 2. Salahuddin SZ, Markham PD, Mikulas P, et al: Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: A study of risk groups and tissue sources. Proc Natl Acad Sci USA 1985;82:5530-5534.Crossref 3. Danner SA, Schuurman HJ, Lange JMA, et al: Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome. Arch Intern Med 1986;146:1133-1136.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Therapy for Acquired Immunodeficiency Syndrome: Implantation of Cultured Thymic Fragments

Phair, John
Archives of Internal Medicine , Volume 146 (6) – Jun 1, 1986
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/therapy-for-acquired-immunodeficiency-syndrome-implantation-of-WopUQNcVJx

References (3)

Publisher
American Medical Association
Copyright
Copyright © 1986 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1986.00360180056007
Publisher site
See Article on Publisher Site

Abstract

Abstract The most serious consequence of infection with the human T-cell leukemia-lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV) is the severely altered immune state underlying the opportunistic diseases that define the acquired immunodeficiency syndrome (AIDS). Control of the spread of HTLV-III/LAV infection in the absence of a vaccine is dependent on risk reduction among homosexual/bisexual males, users of illicit intravenous drugs, and heterosexual sexual partners of these high-risk individuals. Exclusion from the blood supply of potentially infected blood and blood products with screening for antibody to HTLV-III/LAV should prevent approximately 2% of AIDS cases. Therapy of infected individuals with and without AIDS remains an elusive goal but will probably require effective antiviral therapy and immunomodulation. The rationale underlying the attempts to enhance the immune status of these patients is the observation that the defect associated with HTLV-III/LAV infection is due to depletion of T-helper (T4 + ) References 1. Fauci AS, Masur H, Gehman EP, et al: The acquired immunodeficiency syndrome: An update. Ann Intern Med 1985;102: 800-813.Crossref 2. Salahuddin SZ, Markham PD, Mikulas P, et al: Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: A study of risk groups and tissue sources. Proc Natl Acad Sci USA 1985;82:5530-5534.Crossref 3. Danner SA, Schuurman HJ, Lange JMA, et al: Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome. Arch Intern Med 1986;146:1133-1136.Crossref

Journal

Archives of Internal Medicine – American Medical Association

Published: Jun 1, 1986

There are no references for this article.